Skip to main content

Cardiothoracic Research Overview - 2022

2022 Cardiothoracic Research Highlights


The Division of Cardiothoracic Surgery had 123 publications in 2022 and 9 in 2023 as of January

Adult Cardiac 63 1
Pediatric 26 4
Thoracic 25 3
Translational 9 1


Sample of publications

Adult Cardiac

Jentzer JC, Baran DA, Kyle Bohman J, van Diepen S, Radosevich M, Yalamuri S, Rycus P, Drakos SG, Tonna JE.Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):891-903. doi: 10.1093/ehjacc/zuac119.PMID: 36173885

Vigneshwar NG, Masood MF, Vasic I, Krause M, Bartels K, Lucas MT, Bronsert M, Selzman CH, Thompson S, Rove JY, Reece TB, Cleveland JC, Pal JD, Fullerton DA, Aftab M.JTCVS Open. 2022 Dec;12:211-220. doi: 10.1016/j.xjon.2022.08.007. Epub 2022 Sep 8.PMID: 36097635 

Drakos SG, Badolia R, Makaju A, Kyriakopoulos CP, Wever-Pinzon O, Tracy CM, Bakhtina A, Bia R, Parnell T, Taleb I, Ramadurai DKA, Navankasattusas S, Dranow E, Hanff TC, Tseliou E, Shankar TS, Visker J, Hamouche R, Stauder EL, Caine WT, Alharethi R, Selzman CH, Franklin S.Circulation. 2022 Nov 30. doi: 10.1161/CIRCULATIONAHA.121.056600. Online ahead of print.PMID: 36448446

Ciullo AL, Wall N, Taleb I, Koliopoulou A, Stoddard K, Drakos SG, Welt FG, Goodwin M, Van Dyk N, Kagawa H, McKellar SH, Selzman CH, Tonna JE.J Clin Med. 2022 Nov 17;11(22):6802. doi: 10.3390/jcm11226802.PMID: 36431279 


Glenn ET, Harman JR, Marietta J, Lake J, Bailly DK, Ou Z, Griffiths ER, Ware AL.Ann Thorac Surg. 2023 Jan;115(1):126-134. doi: 10.1016/j.athoracsur.2022.08.045. Epub 2022 Sep 17.PMID: 36126719

Hobbs RD, Schultz ML, Loney ML, Verma S, Xiong J, Ohye RG, Bove E, Si MS.J Thorac Cardiovasc Surg. 2023 Jan;165(1):251-259. doi: 10.1016/j.jtcvs.2022.04.022. Epub 2022 May 2.PMID: 35715271

Hobbs RD, Eckhauser AW.J Thorac Cardiovasc Surg. 2023 Jan;165(1):299-300. doi: 10.1016/j.jtcvs.2022.02.023. Epub 2022 Feb 19.PMID: 35260281 No abstract available.

Nelson JS, Fuller S, Kim YY, Maul TM, Najm HK, Scholl FG, Feins EN, Wearden PD, Husain SA, Backer CL, Karamlou T.Ann Thorac Surg. 2022 Nov;114(5):1762-1770. doi: 10.1016/j.athoracsur.2021.09.063. Epub 2021 Nov 3.PMID: 34742732


Mitzman B.Ann Thorac Surg. 2023 Feb;115(2):345-346. doi: 10.1016/j.athoracsur.2022.05.020. Epub 2022 May 28.PMID: 35640672 No abstract available.

Chikwe J, Mitzman B.Ann Thorac Surg. 2022 Dec;114(6):1991-1994. doi: 10.1016/j.athoracsur.2022.10.005.PMID: 36433624 No abstract available.

Pannucci CJ, Fleming KI, Varghese TK Jr, Stringham J, Huang LC, Pickron TB, Prazak AM, Bertolaccini C, Momeni A.Ann Surg. 2022 Dec 1;276(6):e682-e690. doi: 10.1097/SLA.0000000000004589. Epub 2020 Oct 19.PMID: 33086312

Elfaki LA, Luc JGY, Antonoff MB, Cooke DT, Arora RC, Stamp N, Varghese TK Jr, Ouzounian M.JTCVS Open. 2022 Sep;11:265-271. doi: 10.1016/j.xjon.2022.05.005. Epub 2022 May 13.PMID: 35664693 

Translational Science

Kamali R, Gillete K, Tate J, Abhyankar DA, Dosdall DJ, Plank G, Bunch TJ, Macleod RS, Ranjan R.Ann Biomed Eng. 2023 Feb;51(2):329-342. doi: 10.1007/s10439-022-03029-5. Epub 2022 Aug 5.PMID: 35930093

Aromolaran AS.J Cell Physiol. 2022 Dec;237(12):4337-4338. doi: 10.1002/jcp.30658. Epub 2021 Dec 8.PMID: 34888864 

Lange M, Kwan E, Dosdall DJ, MacLeod RS, Bunch TJ, Ranjan R.Front Cardiovasc Med. 2022 Sep 15;9:893752. doi: 10.3389/fcvm.2022.893752. eCollection 2022.PMID: 36187013 

Aromolaran KA, Do J, Bernardi J, Aromolaran AS.Int J Mol Sci. 2022 Jul 22;23(15):8061. doi: 10.3390/ijms23158061.PMID: 35897638 




Adult Cardio

Craig Selzman, MD

  • Title: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
  • Sponsor: BioCardia, Inc

Joseph Tonna, MD

  • Title: ECMO Trial- R01
  • Sponsor: DHHS National Institutes of Health

Jason Glotzbach, MD

  • Title: K08 Resub 
  • Sponsor: DHHS National Institutes of Health

Translational Science

Aromolara Ademuyiwa, PhD

  • Title(s): R01 PA 20-185 Targeting IL-6; Role for Leukorienes
  • Sponsor: DHHS National Institutes of Health 


PI: Craig Selzman, MD 

Project: Post-op Atrial Fibrillation Anticoagulation after Coronary Artery Bypass Surgery (PACeS). 

Background: Post-operative atrial fibrillation (POAF) is the most common arrhythmic complication after coronary artery bypass graft (CABG) surgery. Those who develop POAF remain at high risk of long-term thromboembolic complications. The primary objective is to evaluate the effectiveness and safety of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who have new-onset POAF after CABG. 

Study Design: Participants are eligible if they are at least 18 years of age, underwent isolated CABG for coronary artery disease, and has POAF that persists > 60mins or multiple episodes within 7 days of surgery. If enrolled, they will be followed for 180 days. Participants will be randomized to either OAC plus antiplatelet therapy or just antiplatelet therapy.

Participants randomized to OAC plus antiplatelet will receive: 

  1. OAC w/vit K antagonist (VKA) with INR 2-3 OR
  2. Any direct OAC (apixaban, rivaroxaban, edoaxban, or dabigatran) 

In addition to: 

  1. Aspirin 75-325 mg once -daily OR
  2. P2Y12-inhibitor (clopidogrel or ticagrelor)

For participants randomized antiplatelet therapy only will receive: 

  1. Aspirin 75-325 mg once -daily OR
  2. P2Y12-inhibitor (clopidogrel or ticagrelor)

*Those randomized in this arm may be crossed over to an OAC if they develop recurrent AF after 30 days. 

For more information: 


CT Surgery Research encompasses: 

  • Adult Cardiac
  • Pediatric Cardiac (Primary Children’s)
  • Huntsman team (Huntsman Cancer Institute)
  • Animal Lab Research 
  • Perfusion 

Don’t see your publication or research highlight? Want to share new updates or projects in the works? Please contact Margaret ( to reflect in the next newsletter. 


Hongchao Guo, PhD joins the Division of Cardiothoracic surgery as a faculty member and principal investigator at the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI)

Dr. Guo earned his PhD degree in Cell Biology at Nankai University of China. During his PhD program, he worked at the Institute of Molecular and Cell Biology (IMCB, A-STAR) of Singapore for three years. His PhD work emphasized and focused on stem cell biology and epigenetics. Dr. Guo completed postdoctoral training in Dr. Joseph Wu’s laboratory at Stanford University where the focus was on cellular and genetic mechanisms underlying cardiovascular diseases before joining the University of Utah. 

Dr. Guo has expertise in stem cell biology, genome editing, and next generation sequencing technologies. In his free time, Dr. Guo enjoys running, playing tennis and Tai Chi. 

Dr. Guo’s research interests include: Deciphering the genetic mechanisms underlying cardiovascular diseases. 

Honchao Guo, PhD